CIT-Logo-White Created with Sketch.
News Issue Archive Device Guide Calendar Subscribe Advertising

MENU

Device Guides
Trial Guide
Centers

Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions
Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

Back to Top

Advertisement

Advertisement

EUROPEAN Company Directory


Edwards Lifesciences

One Edwards Way, Irvine, CA 92614

PHONE: (949) 250-2500 | FAX: (949) 756-4656

down-arrow Created with Sketch.
down-arrow Created with Sketch.

Valves / Transcatheter Aortic Valve Implantation

View Chart
Company Name Product Name Valve Diameter (mm) Valve Height (mm) Valve Annulus Size Range (mm) Valve Frame Material Valve Leaflet Material Valve Anticalcification Process Delivery System Name Delivery Access Delivery System Deployment Type Delivery System Size (F) Delivery System Working Length (cm) CE Mark Indications Comments
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve* With Edwards Certitude Delivery System 20, 23, 26, 29 15.5, 18, 20, 22.5 16–28 (diameter by TEE), 18.6–29.5 (area derived diameter) Cobalt chromium Bovine pericardium Yes Edwards Certitude Delivery System Transapical/transaortic Balloon expandable 18, 21 55 Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve* With Edwards Commander Delivery System 20, 23, 26, 29 15.5, 18, 20, 22.5 16–28 (diameter by TEE), 18.6–29.5 (area derived diameter) Cobalt chromium Bovine pericardium Yes Edwards Commander Delivery System Transfemoral Balloon expandable 14, 16 105 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale
Edwards Lifesciences Sapien 3 Ultra Transcatheter Heart Valve* With Certitude Delivery System 20, 23, 26 15.5, 18, 20 16–25 (diameter by TEE), 18.6–26.4 (area derived diameter) Cobalt chromium Bovine pericardium Yes Edwards Certitude Delivery System Transapical/transaortic Balloon expandable 18, 21 55 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale
Edwards Lifesciences Sapien 3 Ultra Transcatheter Heart Valve* With Commander Delivery System 20, 23, 26 15.5, 18, 20 16–25 (diameter by TTE), 18.6–26.4 (area derived diameter) Cobalt chromium Bovine pericardium Yes Edwards Commander Delivery System Transfemoral Balloon expandable 14, 16 105 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale
Edwards Lifesciences Sapien 3 Ultra RESILIA Heart Valve* With Commander Delivery System 20, 23, 26, 29 15.5, 18, 20, 22.5 16–28 (diameter by TEE), 18.6–29.5 (area derived diameter) Cobalt chromium Bovine pericardium Yes Commander Delivery System Transfemoral Balloon expandable Sheath size is 14 and 16 105 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale

Advertisement

Advertisement

Valves / Transcatheter Mitral Valve Repair

View Chart
Company Name Product Name Delivery System Name Delivery Access Delivery System Size (F) Delivery System Working Length (cm) CE Mark Indications Comments
Edwards Lifesciences Edwards Cardioband Mitral Valve Reconstruction System Transseptal Steerable Sheath Transseptal 25.5 82 Indicated for the reconstruction and/or remodeling of pathological mitral valves Implant and delivery system are not available for individual sale
Edwards Lifesciences Edwards Pascal Transcatheter Valve Repair System Pascal Delivery System Transfemoral 22 (septal crossing OD) 79 – –
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve* With Certitude Delivery System Certitude Delivery System Transapical 18, 21 55 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve* With Commander Delivery System Commander Delivery System Transfemoral 14, 16 105 The Edwards Sapien 3, Sapien 3 Ultra, and Sapien 3 Ultra Resilia transcatheter heart valve system is indicated for use in patients with asymptomatic or symptomatic heart disease due to native calcific aortic stenosis at any or all levels of surgical risk for open heart surgery; is indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of an aortic transcatheter bioprosthetic or surgical aortic or mitral bioprosthetic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (ie, predicted risk of surgical mortality ≥ 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical comorbidities unmeasured by the STS risk calculator) *Valve and delivery systems are not available for individual sale

Valves / Transcatheter Pulmonary Valve Repair

View Chart
Company Name Product Name Valve Diameter (mm) Valve Height (mm) Valve Annulus Size Range (mm) Valve Frame Material Valve Leaflet Material Valve Anticalcification Process Delivery System Name Delivery Access Delivery System Deployment Type Delivery System Size (F) Delivery System Working Length (cm) CE Mark Indications Comments
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve 20, 23, 26, 29 15.5, 18, 20, 22.5 16.5–29 Cobalt chromium Bovine pericardium Yes Commander Delivery System Venous access Balloon expandable 14, 16 including provided sheath 105 Indicated for patients with dysfunctional, previously repaired or replaced noncompliant right ventricular outflow tract/pulmonary valve (RVOT/PV) or previously implanted valve in the pulmonic position –
Edwards Lifesciences Sapien 3 Transcatheter Heart Valve With the Alterra Adaptive Prestent 29 49 27–38 Nitinol for the Alterra Adaptive Prestent and cobalt chromium for the valve Bovine pericardium Yes Alterra Delivery System for the Alterra adaptive prestent followed by the Pulmonic Delivery System for the Sapien 3 valve Venous Self expanding followed by balloon expandable 16 for the Alterra Delivery System and 28 for the Pulmonic Delivery system including inline sheath 105 for the Alterra Delivery System and 112 for the Pulmonic Delivery System Indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation as measured by echocardiography who have a native or surgically repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement –

More Categories:

Balloons Catheters Sheaths Stents Structural Heart Valves Wires Other Devices View All

Advertisement

Latest News


April 21, 2026

TECTONIC IDE Trial of Abbott’s Coronary IVL Device Completes Enrollment 

April 21, 2026

Conavi’s IVUS-OCT System for Intravascular Imaging Cleared by FDA

April 20, 2026

KingstronBio Announces First Implant of ProStyle M Transcatheter Mitral Valve System in Confirmatory Study

Most Read Articles


Advances in Wiring and Balloon Technology for Complex PCI

With Raghav Gattani, MD, and Lindsey Cilia, MD, FACC, FSCAI

For Suspected Coronary Calcium Nodules, What Is Your Step-by-Step PCI Strategy?

With Shrilla Banerjee, MD, FRCP, FESC; Jimmy L. Kerrigan, MD, FSCAI, FACC; and Aditya S. Bharadwaj, MD, FACC, FSCAI

New PCI Directions

By Louis Verreault-Julien, MD

Back to Top
Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions
Centers

Coding CTO DES Hypertension Imaging Modalities PCI Pharmacology Radial Regulatory Structural Disease Valvular Interventions

News• Current Issue• Archive• Device Guides• Advertising• About Calendar• Contact• Privacy• Submissions• Subscriptions


Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions.



magazine Created with Sketch.

Free Print Subscriptions

Fill 1 Created with Sketch.

Email Newsletter



twitter-icon LinkedIn Created with Sketch. BlueSky-Circle
Endovascular Today
CIT-Logo-Color Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button